Chemical Recycling of Polyurethane Waste via a Microwave-Assisted Glycolysis Process

In this work, we explored a microwave-assisted glycolysis process to chemically recycle rigid polyurethane (PU) foam waste to obtain a single-phase product with suitable physio-chemical properties as a secondary raw material for the preparation of new rigid PU products. Such an approach was compared to a conventionally heated (ConvH) process, analyzing the performances of different catalysts. The use of microwaves allowed a 94% decrease in the reaction time scale of rigid PU depolymerization, with a concurrent 45% reduction in energy expense. By using a PU/diethylene glycol mass ratio of 1.5, best performances were obtained with a 30 mmol/100g_PU potassium acetate concentration, both in terms of the product viscosity and aromatic amine byproduct content. The glycolysis products recovered were employed in substitution to virgin polyol for rigid PU foam preparation, showing improved compressive strength and comparable thermal insulation properties up to a 30% content with respect to the traditional non-recycled counterpart.

Small intestinal submucosa-derived extracellular matrix as a heterotopic scaffold for cardiovascular applications

Structural cardiac lesions are often surgically repaired using prosthetic patches, which can be biological or synthetic. In the current clinical scenario, biological patches derived from the decellularization of a xenogeneic scaffold are gaining more interest as they maintain the natural architecture of the extracellular matrix (ECM) after the removal of the native cells and remnants. Once implanted in the host, these patches can induce tissue regeneration and repair, encouraging angiogenesis, migration, proliferation, and host cell differentiation. Lastly, decellularized xenogeneic patches undergo cell repopulation, thus reducing host immuno-mediated response against the graft and preventing device failure. Porcine small intestinal submucosa (pSIS) showed such properties in alternative clinical scenarios. Specifically, the US FDA approved its use in humans for urogenital procedures such as hernia repair, cystoplasties, ureteral reconstructions, stress incontinence, Peyronie's disease, penile chordee, and even urethral reconstruction for hypospadias and strictures. In addition, it has also been successfully used for skeletal muscle tissue reconstruction in young patients. However, for cardiovascular applications, the results are controversial. In this study, we aimed to validate our decellularization protocol for SIS, which is based on the use of Tergitol 15 S 9, by comparing it to our previous and efficient method (Triton X 100), which is not more available in the market. For both treatments, we evaluated the preservation of the ECM ultrastructure, biomechanical features, biocompatibility, and final bioinductive capabilities. The overall analysis shows that the SIS tissue is macroscopically distinguishable into two regions, one smooth and one wrinkle, equivalent to the ultrastructure and biochemical and proteomic profile. Furthermore, Tergitol 15 S 9 treatment does not modify tissue biomechanics, resulting in comparable to the native one and confirming the superior preservation of the collagen fibers. In summary, the present study showed that the SIS decellularized with Tergitol 15 S 9 guarantees higher performances, compared to the Triton X 100 method, in all the explored fields and for both SIS regions: smooth and wrinkle.